|
1
|
Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study.
|
Hepatology
|
2013
|
2.30
|
|
2
|
Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival.
|
J Clin Oncol
|
2006
|
1.75
|
|
3
|
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
|
J Clin Oncol
|
2008
|
1.54
|
|
4
|
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias.
|
Br J Haematol
|
2003
|
1.44
|
|
5
|
Update on the treatment of neuroendocrine tumors.
|
Expert Rev Anticancer Ther
|
2003
|
1.33
|
|
6
|
Sentinel node in breast cancer procedural guidelines.
|
Eur J Nucl Med Mol Imaging
|
2007
|
1.30
|
|
7
|
Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer.
|
Eur J Nucl Med Mol Imaging
|
2004
|
1.25
|
|
8
|
90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
|
Cancer Immunol Immunother
|
2005
|
1.00
|
|
9
|
Somatostatin receptor SPECT.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.91
|
|
10
|
Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
|
Nucl Med Commun
|
2004
|
0.87
|
|
11
|
FDG-PET for axillary lymph node staging in primary breast cancer.
|
Eur J Nucl Med Mol Imaging
|
2004
|
0.86
|
|
12
|
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
|
Eur J Cancer
|
2008
|
0.86
|
|
13
|
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies.
|
J Nucl Med
|
2012
|
0.86
|
|
14
|
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
|
Cancer Biother Radiopharm
|
2007
|
0.85
|
|
15
|
(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts.
|
Nucl Med Biol
|
2009
|
0.84
|
|
16
|
Diagnostic and therapeutic aspects of iatrogenic hypoparathyroidism.
|
Tumori
|
2004
|
0.84
|
|
17
|
EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin).
|
Eur J Nucl Med Mol Imaging
|
2007
|
0.83
|
|
18
|
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
|
Eur J Nucl Med Mol Imaging
|
2015
|
0.82
|
|
19
|
Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.81
|
|
20
|
Simple preparation and purification of ethanol-free solutions of 3'-deoxy-3'-[18F]fluorothymidine by means of disposable solid-phase extraction cartridges.
|
Nucl Med Biol
|
2011
|
0.80
|
|
21
|
The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.
|
Eur J Nucl Med Mol Imaging
|
2006
|
0.80
|
|
22
|
Evaluation of circulating calcitonin: analytical aspects.
|
Tumori
|
2004
|
0.80
|
|
23
|
Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer.
|
J Nucl Med
|
2011
|
0.79
|
|
24
|
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.
|
Anticancer Res
|
2003
|
0.79
|
|
25
|
Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.79
|
|
26
|
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
|
Oncology
|
2013
|
0.78
|
|
27
|
Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.
|
J Pathol
|
2003
|
0.78
|
|
28
|
Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide.
|
Eur J Endocrinol
|
2003
|
0.78
|
|
29
|
The role of radionuclide therapy in medullary thyroid cancer.
|
Tumori
|
2004
|
0.78
|
|
30
|
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient.
|
J Cancer Res Clin Oncol
|
2013
|
0.77
|
|
31
|
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
|
Int J Oncol
|
2003
|
0.77
|
|
32
|
Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
|
Support Care Cancer
|
2006
|
0.77
|
|
33
|
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
|
J Clin Oncol
|
2013
|
0.76
|
|
34
|
New perspectives in the treatment of neuroendocrine tumours.
|
Anticancer Res
|
2012
|
0.76
|
|
35
|
Somatostatin receptor scintigraphy for bronchial carcinoid follow-up.
|
Clin Nucl Med
|
2003
|
0.76
|
|
36
|
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
|
Biomed Pharmacother
|
2004
|
0.76
|
|
37
|
Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?
|
Eur J Nucl Med Mol Imaging
|
2016
|
0.75
|
|
38
|
Nuclear medicine imaging in breast cancer: current strategies and future directions.
|
Oncology (Williston Park)
|
2009
|
0.75
|
|
39
|
Assessing anti-cancer treatment by positron emission tomography: primum non nocere.
|
Nucl Med Commun
|
2004
|
0.75
|
|
40
|
A female survivor of childhood medulloblastoma presenting with growth-hormone-induced edema and inflammatory lesions: a case report.
|
J Med Case Rep
|
2009
|
0.75
|
|
41
|
Critical aspects of immunoradiometric thyroglobulin assays.
|
Tumori
|
2004
|
0.75
|
|
42
|
Radioiodine therapy a successful tool in treating thyroid cancer. Foreword.
|
Q J Nucl Med Mol Imaging
|
2009
|
0.75
|
|
43
|
Diagnostic procedures in the follow-up of patients affected by MEN type 2.
|
Tumori
|
2004
|
0.75
|
|
44
|
FDG-PET in thyroid cancer.
|
Tumori
|
2004
|
0.75
|
|
45
|
Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.75
|